Clinical Trial Update: Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) [Phase 3]

View source ↗

Summary

Phase 3 trial of pertuzumab in platinum-resistant, HER3 mRNA–positive epithelial ovarian cancer (PENELOPE) has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-11-23